Noile-Immune Biotech Inc. (TYO:4893)

Revenue by Segment

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cancer Immunotherapy Drug	7.59M
Cancer Immunotherapy Drug Growth	-97.61%

Revenue by Geography

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Japan	7.59M
Japan Growth	-97.61%

Data Source: Finnhub Last updated: Mar 31, 2026

Financial data is provided by Finnhub and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 20, 2026

Data Sources Report a data error